Vanguard Group Inc. Purchases 15,300 Shares of Integer Holdings Co. (NYSE:ITGR)

Vanguard Group Inc. lifted its position in shares of Integer Holdings Co. (NYSE:ITGR) by 0.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,843,992 shares of the medical equipment provider’s stock after purchasing an additional 15,300 shares during the quarter. Vanguard Group Inc. owned 11.53% of Integer worth $301,484,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Integer by 0.6% during the first quarter. BlackRock Inc. now owns 6,018,773 shares of the medical equipment provider’s stock worth $484,933,000 after acquiring an additional 38,664 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Integer by 8.9% during the third quarter. Victory Capital Management Inc. now owns 1,632,549 shares of the medical equipment provider’s stock worth $128,041,000 after acquiring an additional 133,898 shares during the period. State Street Corp raised its holdings in shares of Integer by 1.6% during the second quarter. State Street Corp now owns 1,356,627 shares of the medical equipment provider’s stock worth $120,211,000 after acquiring an additional 21,795 shares during the period. Silvercrest Asset Management Group LLC raised its holdings in shares of Integer by 2.7% during the second quarter. Silvercrest Asset Management Group LLC now owns 1,024,370 shares of the medical equipment provider’s stock worth $90,769,000 after acquiring an additional 27,076 shares during the period. Finally, Macquarie Group Ltd. raised its holdings in shares of Integer by 0.3% during the first quarter. Macquarie Group Ltd. now owns 972,726 shares of the medical equipment provider’s stock worth $75,386,000 after acquiring an additional 3,361 shares during the period. 99.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

ITGR has been the topic of a number of research analyst reports. CL King initiated coverage on shares of Integer in a report on Thursday, March 14th. They set a “buy” rating and a $137.00 price objective on the stock. KeyCorp lowered their price target on shares of Integer from $125.00 to $123.00 and set an “overweight” rating on the stock in a research note on Friday, February 16th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $105.50.

Integer Stock Up 3.2 %

Shares of ITGR stock opened at $115.11 on Thursday. The firm has a market capitalization of $3.84 billion, a P/E ratio of 42.79, a PEG ratio of 1.44 and a beta of 1.09. The firm’s fifty day moving average price is $107.25 and its two-hundred day moving average price is $94.25. Integer Holdings Co. has a 1 year low of $69.40 and a 1 year high of $118.15. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.05. The company had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. Integer had a net margin of 5.68% and a return on equity of 10.80%. Integer’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.11 EPS. On average, equities analysts predict that Integer Holdings Co. will post 5.28 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.